The most effective dose led to a statistically meaningful decrease in brain plaques.
. This type of medication targets the fundamental pathophysiology of the disease and is considered a significant development in the effort to successfully treat Alzheimer's disease."Alzheimer’s disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones," said Billy Dunn, M.D., director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research.
Researchers assessed Leqembi's effectiveness in a trial involving 856 patients with Alzheimer's disease. Treatment started with patients with mild cognitive impairment or mild dementia stage of the disease and confirmed the presence of amyloid beta pathology. ARIA is typically asymptomatic, but in rare cases, it can cause serious and potentially fatal complications. The most common symptom of ARIA is temporary swelling in some areas of the brain that usually resolves on its own and may be accompanied by small bleeding spots on or in the brain. However, some individuals may experience symptoms such as headaches, confusion, dizziness, changes in vision, nausea, and seizures.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
The FDA approves an Alzheimer's drug that appears to modestly slow the diseaseThe Food and Drug Administration has approved an Alzheimer's drug that appears to modestly slow down the disease. (Story aired on Weekend Edition Saturday on Jan. 6, 2023.)
Consulte Mais informação »
FDA approves Alzheimer’s drug lecanemab amid safety concernsReports of deaths potentially linked to the treatment have cast a shadow on what many hail as a landmark approval.
Consulte Mais informação »
FDA approves new Alzheimer’s drug, but its price tag is raising concerns among advocatesA new breakthrough Alzheimer's drug is giving people hope, but the cost is raising concern among advocates.
Consulte Mais informação »
FDA Commissioner Denies Wrongdoing in Approval Process for Biogen Alzheimer’s Drug AduhelmFDA Commissioner Robert Califf defended the decision to approve the controversial Alzheimer’s drug Aduhelm after a congressional probe found “inappropriate” collaboration between the agency and Biogen
Consulte Mais informação »
US to start training Ukrainians on Patriot system on US soil next weekThe U.S. intends to begin training with Ukrainian soldiers next week on the sophisticated Patriot missile system first pledged last month.
Consulte Mais informação »
U.S. must act on the Brazil coupsters among us | Will Bunch NewsletterDaily News | U.S. must act on the Brazil coupsters among us | Will Bunch Newsletter
Consulte Mais informação »